Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma

被引：2

作者：

Rosell, Rafael ^{[1
,2
]}

Karachaliou, Niki ^{[2
,3
]}

机构：

[1] Hosp Germans Ramon y Cajal, Catalan Inst Oncol, Barcelona 08916, Spain

[2] Germans Trias & Pujol Res Inst, Barcelona, Spain

[3] Univ Hosp Sagrat Cor, Inst Oncol, QuironSalud Grp, Barcelona, Spain

来源：

LANCET RESPIRATORY MEDICINE | 2018年 / 6卷 / 09期

关键词：

MUTATION; CANCER;

D O I：

10.1016/S2213-2600(18)30292-3

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：649 / 651

页数：4

共 50 条

[31] Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma
Zhai, H.
Moore, D.
Jamal-Hanjani, M.
ANNALS OF ONCOLOGY, 2020, 31 (02) : 169 - 170
[32] PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma
Isobe, Kazutoshi
Kakimoto, Atsushi
Mikami, Tetuo
Kaburaki, Kyohei
Kobayashi, Hiroshi
Yoshizawa, Takahiro
Nakano, Yuta
Makino, Takashi
Otsuka, Hajime
Sano, Go
Sugino, Keishi
Sakamoto, Susumu
Takai, Yujiro
Tochigi, Naobumi
Iyoda, Akira
Homma, Sakae
ONCOLOGY REPORTS, 2018, 40 (01) : 331 - 338
[33] Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma
Kaira, Kyoichi
Imai, Hisao
Kagamu, Hiroshi
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1177 - 1182
[34] Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer
Kok, Peey-Sei
Lee, Kirsty
Lord, Sally
John, Thomas
Marschner, Ian
Wu, Yi-Long
Mok, Tony S. K.
Lee, Chen Khoon
LUNG CANCER, 2022, 163 : 14 - 18
[35] Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
Duan, Jianchun
Xu, JiaChen
Wang, Zhijie
Bai, Hua
Cheng, Ying
An, Tongtong
Gao, Hongjun
Wang, Kai
Zhou, Qing
Hu, Yanping
Song, Yong
Ding, Cuimin
Peng, Feng
Liang, Li
Hu, Yi
Huang, Cheng
Zhou, Caicun
Shi, Yuankai
Han, Jiefei
Wang, Di
Tian, Yanhua
Yang, Zhenlin
Zhang, Li
Chuai, Shaokun
Ye, Junyi
Zhu, Guanshan
Zhao, Junhui
Wu, Yi-Long
Wang, Jie
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (12) : 1857 - 1870
[36] Squamous cell histological transformation beyond EGFR TKI treatment against EGFR-mutant lung adenocarcinoma
Koba, Hayato
Nishikawa, Shingo
Yoneda, Taro
Sone, Takashi
Kimura, Hideharu
Kasahara, Kazuo
ANNALS OF ONCOLOGY, 2015, 26 : 138 - 138
[37] Mechanism underlying acquisition of dual resistance to EGFR and MET inhibitors by EGFR-mutant lung adenocarcinoma cells
Yamaoka, Toshimitsu
Ohmori, Tohru
Ohba, Motoi
Murata, Yasunori
Kishino, Yasunari
Kusumoto, Sojiro
Ishida, Hiroo
Ohnishi, Tsukasa
Sasakii, Yasutsuna
CANCER RESEARCH, 2016, 76
[38] Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Lin, Jessica J.
Cardarella, Stephanie
Lydon, Christine A.
Dahlberg, Suzanne E.
Jackman, David M.
Jaenne, Pasi A.
Johnson, Bruce E.
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 556 - 565
[39] T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Zungsontiporn, N.
Santisukwongchote, S.
Sitthideatphaiboon, P.
Leelayuwatanakul, N.
Korphaisarn, K.
Chantranuwat, P.
Sriuranpong, V.
Vinayanuwattikun, C.
ANNALS OF ONCOLOGY, 2023, 34 : S250 - S250
[40] COMPREHENSIVE METHYLOME ANALYSIS OF EGFR-MUTANT PRIMARY LUNG ADENOCARCINOMA AND MATCHED BRAIN METASTASIS
Mamatjan, Yasin
Cabanero, Michael
Zuccato, Jeffrey
Weiss, Jessica
Karimi, Shirin
Sorotsky, Hadas
Tsao, Ming
Aldape, Kenneth
Shepherd, Frances
Zadeh, Gelareh
NEURO-ONCOLOGY, 2019, 21 : 58 - 58

← 1 2 3 4 5 →